Clinical Evidence and Potential Neurobiological Underpinnings of Unresolved Symptoms of Depression
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Recent data indicate that more than 65% of patients with major depressive disorder (MDD) fail to achieve remission. This article reviews research on the current understanding and management of residual symptoms, i.e., subthreshold depressive symptoms present after recovery from a major depressive episode. DATA SOURCES: MEDLINE (1966 to June 2006) was searched using combinations of the following search terms: major depressive disorder, residual symptoms, remission, response, tachyphylaxis, antidepressant, algorithm, treatment, responsiveness, serotonin, norepinephrine, and dopamine. STUDY SELECTION: All relevant articles that were published in English and reported original study data related to residual symptoms in MDD were included. DATA EXTRACTION: Studies were examined for data related to the prevalence, presentation, consequences, treatment, and neurobiological underpinnings of residual symptoms associated with MDD. DATA SYNTHESIS: Residual symptoms are common among patients treated for MDD who do not achieve full remission. Incomplete remission is associated with increased risk of relapse, suicide, functional impairment, and higher use of health care resources. Several factors, including "downstream" neurochemical mechanisms and clinical factors such as lack of adherence, contribute to the high prevalence of residual symptoms. Various clinical strategies, including switching and substitution antidepressant therapies, are used to address unresolved depressive symptoms. Individual differences in therapeutic response contribute to inadequate treatment and are linked to numerous clinical and neurobiological factors, including noncompliance, underdosing, intolerance, disturbances in neural circuitry, and genetic variability in neurotransmitters. CONCLUSIONS: Future research is needed to more precisely characterize residual symptoms and their underlying biochemical and molecular mechanisms in order to develop more effective treatment methods.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are three broad disease models proposed by the literature to explain treatment resistance, summarised in Figure 5 (see eAppendix 3 for search details). 48–51”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [49]
Citations
Cites
Still being checked.
Cited by
Adult ADHD and comorbid disorders: clinical implications of a dimensional approach
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1463-3 · Cited by 732
“Purely serotonergic activity lowers dopamine and norepinephrine levels via effects on 5-HT2C and 5-HT2A interneurons, respectively [83].”
BackgroundMonoamine neurocircuitry in depression and strategies for new treatments
Hamon, M., & Blier, P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.009 · Cited by 594
Self-citationMcMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.011 · Cited by 448
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 427
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Neurobiology of depression, fibromyalgia and neuropathic pain
Maletic, V. (2009) · Frontiers in Bioscience · doi:10.2741/3598 · Cited by 366
McCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.001 · Cited by 365
Hellemans, K. G. C., Sliwowska, J. H., Verma, P., & Weinberg, J. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.06.004 · Cited by 347
Cognitive dysfunction in unipolar depression: Implications for treatment
Trivedi, M. H., & Greer, T. L. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.09.012 · Cited by 294
“2) (Trivedi et al., 2008) Serotonergic neurons appear to modulate neuronal activity in the prefrontal cortex via opposing actions of 5-HT1a and 5-HT2a receptors on pyramidal cells and interneurons.”
BackgroundSelf-citationRéus, G. Z., Jansen, K., Titus, S., Carvalho, A. F., Gabbay, V., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.05.007 · Cited by 221
Li, C.-T., Lin, C.-P., Chou, K.-H., Chen, I.-Y., Hsieh, J.-C., Wu, C.-L., Lin, W.-C., & Su, T.-P. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.11.021 · Cited by 213
Wang, Y.-S., Shen, C.-Y., & Jiang, J.-G. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104520 · Cited by 184
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
Pompili, M., Serafini, G., Innamorati, M., Möller-Leimkühler, A. M., Giupponi, G., Girardi, P., Tatarelli, R., & Lester, D. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0108-z · Cited by 161
Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness
Albert, P. R., Le François, B., & Millar, A. M. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-21 · Cited by 150
de Diego-Adeliño, J., Pires, P., Gómez-Ansón, B., Serra-Blasco, M., Vives-Gilabert, Y., Puigdemont, D., Martín-Blanco, A., Álvarez, E., Pérez, V., & Portella, M. J. (2014) · Psychological Medicine · doi:10.1017/s003329171300158x · Cited by 147
The Economic Burden of Treatment-Resistant Depression
Olchanski, N., McInnis Myers, M., Halseth, M., Cyr, P. L., Bockstedt, L., Goss, T. F., & Howland, R. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.001 · Cited by 146
Relevance of Norepinephrine–Dopamine Interactions in the Treatment of Major Depressive Disorder
El Mansari, M., Guiard, B. P., Chernoloz, O., Ghanbari, R., Katz, N., & Blier, P. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00146.x · Cited by 146
Self-citationAstroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis
Kim, R., Healey, K. L., Sepulveda-Orengo, M. T., & Reissner, K. J. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.002 · Cited by 141
Mesenchymal stem cells increase hippocampal neurogenesis and counteract depressive-like behavior
Tfilin, M., Sudai, E., Merenlender, A., Gispan, I. H., Yadid, G., & Turgeman, G. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.110 · Cited by 139
Mahableshwarkar, A. R., Jacobsen, P. L., & Chen, Y. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761600 · Cited by 135
Insomnia and depression: a multifaceted interplay
Manber, R., & Chambers, A. S. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0066-1 · Cited by 134
“Disturbed sleep is a common residual symptom following depression treatment A substantial percentage (30% to 50%) of depressed patients continue to have residual symptoms even when treated to remission, with sleep disturbance being one of the most common [ 21 ].”
BackgroundThe role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications
Felger, J. C. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_13 · Cited by 115
Mondino, M., Bennabi, D., Poulet, E., Galvao, F., Brunelin, J., & Haffen, E. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.876514 · Cited by 114
Heisler, J. M., & O’Connor, J. C. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.022 · Cited by 113
Yin, L., Xu, X., Chen, G., Mehta, N. D., Haroon, E., Miller, A. H., Luo, Y., Li, Z., & Felger, J. C. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.05.011 · Cited by 110
Treatment-Resistant Depression Revisited: A Glimmer of Hope
Halaris, A. E., Sohl, E., & Whitham, E. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020155 · Cited by 109
Weisler, R., Joyce, J. M., McGill, L., Lazarus, A., Szamosi, J., Eriksson, H., & Moonstone Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900020307 · Cited by 108
Antidepressant effects of TNF-α blockade in an animal model of depression
Krügel, U., Fischer, J., Radicke, S., Sack, U., & Himmerich, H. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.007 · Cited by 104
Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy
Albert (2010) · Frontiers in Neuroscience · doi:10.3389/fnins.2010.00035 · Cited by 103
Role of Inflammation in Depression and Treatment Implications
Felger, J. C. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_166 · Cited by 103
Coplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90
“The reader is referred to other sources (Trivedi et al., 2008) for non-response to other agents.”
BackgroundMethodInfluentialLiebowitz, M., Lam, R. W., Lepola, U., Datto, C., Sweitzer, D., & Eriksson, H. (2010) · Depression and Anxiety · doi:10.1002/da.20740 · Cited by 86
Neurotransmitter Targeting in the Treatment of Depression
Blier, P. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12084su1c.04 · Cited by 84
Self-citationPrefrontal glucose metabolism in medication-resistant major depression
Li, C.-T., Su, T.-P., Wang, S.-J., Tu, P.-C., & Hsieh, J.-C. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.140434 · Cited by 84
Katzman, M., & Sternat, T. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111818 · Cited by 83
Psychosocial stress and anxiety in musculoskeletal pain patients with and without depression
Poleshuck, E. L., Bair, M. J., Kroenke, K., Damush, T. M., Tu, W., Wu, J., Krebs, E. E., & Giles, D. E. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2008.10.003 · Cited by 83
Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 82
Immune and Neuroprotective Effects of Physical Activity on the Brain in Depression
Phillips, C., & Fahimi, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00498 · Cited by 81
Cooper, J. A., Tucker, V. L., & Papakostas, G. I. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113514878 · Cited by 76
Actigraphically measured psychomotor slowing in depression: systematic review and meta-analysis
Wüthrich, F., Nabb, C. B., Mittal, V. A., Shankman, S. A., & Walther, S. (2022) · Psychological Medicine · doi:10.1017/s0033291722000903 · Cited by 75
The CRF system as a therapeutic target for neuropsychiatric disorders
Sanders, J., & Nemeroff, C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.004 · Cited by 72
Lin, W., Chou, K., Chen, H.-L., Huang, C., Lu, C.-H., Li, S.-H., Wang, Y., Cheng, Y.-F., Lin, C., & Chen, C.-C. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2011.05.009 · Cited by 71
Understanding the role of serotonin in psychiatric diseases
Marazziti, D. (2017) · F1000Research · doi:10.12688/f1000research.10094.1 · Cited by 69
The Impact of Residual Symptoms in Major Depression
Israel, J. A. (2010) · Pharmaceuticals · doi:10.3390/ph3082426 · Cited by 67
Pharmacokinetics of Sertraline Across Pregnancy and Postpartum
Freeman, M. P., Nolan, P. E., Davis, M. F., Anthony, M., Fried, K., Fankhauser, M., Woosley, R. L., & Moreno, F. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818d2048 · Cited by 66
Involvement of pGluR1, EAAT2 and EAAT3 in offspring depression induced by prenatal stress
Zhang, X., Jia, N., Zhao, X. Y., Tang, G. K., Guan, L. X., Wang, D., Sun, H., Li, H., & Zhu, Z. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.031 · Cited by 65
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Briley, M., & Blier, P. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19613 · Cited by 63
Self-citationZajecka, J., Kornstein, S. G., & Blier, P. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12059ah1 · Cited by 61
Self-citationKanarik, M., Grimm, O., Mota, N. R., Reif, A., & Harro, J. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104757 · Cited by 58
Adult attention deficit hyperactivity disorder: a comprehensive review
Williams, O. C. A., Prasad, S., McCrary, A., Jordan, E., Sachdeva, V., Deva, S., Kumar, H., Mehta, J., Neupane, P., & Gupta, A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000631 · Cited by 58
van Noorden, M. S., Giltay, E. J., den Hollander-Gijsman, M. E., van der Wee, N. J. A., van Veen, T., & Zitman, F. G. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.12.007 · Cited by 52
Levkovitz, Y., Alpert, J. E., Brintz, C. E., Mischoulon, D., & Papakostas, G. I. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.059 · Cited by 51
Reus, G. Z., de Moura, A. B., Silva, R. H., Resende, W. R., & Quevedo, J. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170630164715 · Cited by 49
Thase, M. E., Trivedi, M. H., Nelson, J. C., Fava, M., Swanink, R., Tran, Q.-V., Pikalov, A., Yang, H., Carlson, B. X., Marcus, R. N., et al. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0603 · Cited by 47
Self-citationAlbert, P., & Fiori, L. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660740 · Cited by 46
Engaging homeostatic plasticity to treat depression
Workman, E. R., Niere, F., & Raab‐Graham, K. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.225 · Cited by 46
Li, P., Hsiao, I.-T., Liu, C.-Y., Chen, C.-H., Huang, S.-Y., Yen, T.-C., Wu, K.-Y., & Lin, K.-J. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0273-4 · Cited by 46
Tachyphylaxis in major depressive disorder: A review of the current state of research
Kinrys, G., Gold, A. K., Pisano, V. D., Freeman, M. P., Papakostas, G. I., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.357 · Cited by 45
Antidepressant-like effects of buprenorphine in rats are strain dependent
Browne, C. A., van Nest, D. S., & Lucki, I. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.10.014 · Cited by 45
Güleç, M., Selvı, Y., Boysan, M., Aydın, A., Beşiroğlu, L., & Ağargün, M. Y. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.056 · Cited by 45
Rosas-Sánchez, G. U., Germán-Ponciano, L. J., Guillén-Ruiz, G., Cueto‐Escobedo, J., Limón-Vázquez, A. K., Rodríguez‐Landa, J. F., & Soria-Fregozo, C. (2024) · Biomedicines · doi:10.3390/biomedicines12122744 · Cited by 43
Dobkin, R. D., Menza, M. A., Bienfait, K., Gara, M. A., Marín, H., Mark, M. H., Dicke, A., & Friedman, J. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181e448f7 · Cited by 43
Wu, Y. C., Hill, R., Klug, M., & van den Buuse, M. (2012) · Brain Research · doi:10.1016/j.brainres.2012.03.011 · Cited by 40
Song, J., Hou, X., Hu, X., Lu, C., Liu, C., Wang, J., Liu, W., Teng, L., & Wang, D. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.10.001 · Cited by 40
Jin, Z., Gao, N., Li, X., Tang, Y. C., Xiong, J., Chen, H., Xue, R., & Li, Y. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.005 · Cited by 39
Association between residual symptoms and social functioning in patients with depression
Wang, Y., Wang, G., Zhang, N., Jizhong, H., Wu, W., Jia, F., Liu, T., Gao, C., Hu, J., Hong, W., et al. (2020) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2020.152164 · Cited by 34
Lee, M.-K., Ryu, Y. H., Cho, W. G., Kang, Y. W., Lee, S. J., Jeon, T. J., Lyoo, C. H., Kim, C. H., Kim, D. G., Lee, K., et al. (2015) · Synapse · doi:10.1002/syn.21834 · Cited by 33
Thakurdesai, P. A., Kalshetti, P. B., Alluri, R., & Mohan, V. (2015) · Pharmacognosy Magazine · doi:10.4103/0973-1296.168980 · Cited by 33
Dornbierer, D. A., Marten, L., Mueller, J., Aicher, H. D., Mueller, M. J., Boxler, M., Kometer, M., Kosanic, D., von Rotz, R., Puchkov, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1246892 · Cited by 32
“Still, fewer than 50% of all patients with depression show full remission with optimized standard treatment, and often, these medications have considerable side effects (Trivedi et al., 2008).”
BackgroundBowens, N. H., Heydendael, W., Bhatnagar, S., & Jacobson, L. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.10.032 · Cited by 32
Guo, Z., Long, T., Yao, J., Li, Y., Xiao, L., & Chen, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1337876 · Cited by 30
Borentain, S., Williamson, D., Turkoz, I., Popova, V., McCall, W. V., Mathews, M., & Wiegand, F. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s339090 · Cited by 29
Rosas-Sánchez, G. U., German-Ponciano, L. J., Guillén-Ruiz, G., Cueto-Escobedo, J., Limón-Vázquez, A. K., Rodríguez-Landa, J. F., & Soria-Fregozo, C. (2024) · doi:10.20944/preprints202410.2591.v1 · Cited by 28
Benvenuti, A., Rucci, P., Calugi, S., Cassano, G. B., Miniati, M., & Frank, E. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328333ee8e · Cited by 28
Padilla‐Tolentino, E., Shumake, J., Barrett, D. W., Sheridan, E. C., & Gonzalez-Lima, F. (2011) · Brain Research · doi:10.1016/j.brainres.2011.02.080 · Cited by 27
Levkovitz, Y., Alpert, J. E., Brintz, C., Mischoulon, D., & Papakostas, G. I. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.03.006 · Cited by 26
Do Manualized Treatments for Depression Reduce Insomnia Symptoms?
Yon, A., Scogin, F. R., DiNapoli, E. A., McPherron, J. A., Areán, P. A., Bowman, D., Jamison, C. S., Karpe, J. A., Latour, D., Reynolds, C. F., et al. (2014) · Journal of Clinical Psychology · doi:10.1002/jclp.22062 · Cited by 25
The network analysis of depressive symptoms before and after two weeks of antidepressant treatment
Zhou, J. L., Liu, S., Mayes, T. L., Feng, Y., Fang, M., Xiao, L., & Wang, G. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.11.059 · Cited by 25
Aydın, E. P., Genç, A., Dalkıran, M., Uyar, E. T., Deniz, İ., Özer, Ö. A., & Karamustafalıoğlu, O. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.025 · Cited by 24
Epstein, I., Szpindel, I., & Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70003-4 · Cited by 23
Inadequate Response to Antidepressant Treatment in Major Depressive Disorder
Papakostas, G. I., Jackson, W., Rafeyan, R., & Trivedi, M. H. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.ot19037com5 · Cited by 23
Self-citationChen, R.-A., Lee, C., Lee, Y., Hung, C., Huang, Y., Lin, P., Lee, S.-Y., & Wang, L. (2019) · PeerJ · doi:10.7717/peerj.7432 · Cited by 22
Targeting Treatment-Resistant Depression
Mathys, M. L., & Mitchell, B. G. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426972 · Cited by 22
Choice of Treatment with Antidepressants: Influencing Factors
Himmerich, H., & W. Wranik, D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523653 · Cited by 21
Palm, D., Uzoni, A., Simon, F., Fischer, M., Coogan, A., Tucha, O., Thome, J., & Faltraco, F. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.007 · Cited by 20
Kennedy, S. H., Young, A. H., & Blier, P. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.048 · Cited by 20
Self-citationLi, C., Cheng, C., Lin, H., Yeh, S. H., Jeng, J., Wu, H.-T., Bai, Y., Tsai, S., Su, T., & Fitzgerald, P. B. (2023) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2023.103686 · Cited by 20
Antidepressant-like effect of 4-hydroxyisoleucine from Trigonella foenum graecum L. seeds in mice
Gaur, V., Bodhankar, S. L., Mohan, V., & Thakurdesai, P. A. (2012) · Biomedicine & Aging Pathology · doi:10.1016/j.biomag.2012.07.002 · Cited by 20
Marchetti, L., Lauria, M., Caberlotto, L., Musazzi, L., Popoli, M., Mathé, A. A., Domenici, E., & Carboni, L. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.11.004 · Cited by 19
Nichols, A. I., Tourian, K. A., Tse, S., & Paul, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.535810 · Cited by 18
Yang, H., Sinicropi-Yao, L., Chuzi, S. E., Youn, S. J., Clain, A. J., Baer, L., Chen, Y., McGrath, P. J., Fava, M., & Papakostas, G. I. (2010) · Annals of General Psychiatry · doi:10.1186/1744-859x-9-10 · Cited by 17
Spinal mechanism of micturition reflex inhibition by naftopidil in rats
Sugaya, K., Nishijima, S., Kadekawa, K., Ashitomi, K., Ueda, T., & Yamamoto, H. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.09.008 · Cited by 17
Promising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 16
Knockout of NPFFR2 Prevents LPS-Induced Depressive-Like Responses in Mice
Yu, Z., Lin, Y., & Chen, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147611 · Cited by 16
Chappell, K., Colle, R., Bouligand, J., Trabado, S., Fève, B., Becquemont, L., Corruble, E., & Verstuyft, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010497 · Cited by 16
Therapeutic Armamentarium for Treating Depression
Howland, R. H. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2176 · Cited by 15
Petit, A., Asmar, K. E., David, D. J. P., Gardier, A. M., Becquemont, L., Fève, B., Verstuyft, C., & Corruble, E. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.006 · Cited by 14
Taş, S., Döndaş, H. A., Döndaş, N. Y., Poyraz, S., Taşkın‐Tok, T., Demiray, G. A., Belveren, S., İnce, T., Demir, Y., Yılmaz, M. B., et al. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2559573 · Cited by 13
Metadata
- Authors
- Trivedi, M. H., Hollander, E., Nutt, D., & Blier, P.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Bristol (GB)
- University of Ottawa (CA)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-02-15
- Volume
- 69
- Issue
- 2
- Pages
- 246-258
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2041144155
- Cited by
- 153
- References
- 0
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 8 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 6 · 2017: 11 · 2016: 9 · 2015: 9 · 2014: 11 · 2013: 12 · 2012: 9
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- residual depressive symptoms, major depressive disorder, incomplete remission, antidepressant response, antidepressant switching, tachyphylaxis, medication adherence, underdosing, relapse risk, suicide risk, functional disability, health care utilization, neurobiological mechanisms, serotonin, norepinephrine, dopamine, neural circuits
- MeSH terms
- Algorithms, Antidepressive Agents, Anxiety, Cognition Disorders, Decision Trees, Depression, Depressive Disorder, Dopamine, Humans, Hypothalamo-Hypophyseal System, Norepinephrine, Pituitary-Adrenal System, Serotonin, Sleep Wake Disorders, Neurotransmitter Uptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Adrenergic Uptake Inhibitors, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.